Protez begins Phase II study for injectable antibiotic

The trial is projected to enroll approximately 100 adult patients at 20 sites in the US. The study will evaluate the safety and efficacy of PZ-601 in patients with infections including cellulitis, abscesses, infected wounds and ulcers.

Clarence Young, chief medical officer of Protez, said: “Feedback from clinical experts indicates that PZ-601 has the potential to combat infections that represent a significant health risk to patients across the globe, such as infections due to methicillin-resistant Staphylococcus aureus (MRSA) and multidrug- resistant Gram negative organisms.”